Our work demonstrates that treatment with tamoxifen, fulvestrant, or AZD9496 may radiosensitize ER+ breast cancer models through induction of senescence and inhibition of NHEJ-mediated repair. This evidence concerns the gene ESR1 and breast carcinoma.